[
  {
    "ts": "2025-12-19T14:51:15+00:00",
    "headline": "Pfizer (PFE) CEO’s Struggling Because Of “a Good Hand,” Says Jim Cramer",
    "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them. On Tuesday, the stock dipped by 5.2% after the firm released its full-year 2026 guidance. The […]",
    "url": "https://finance.yahoo.com/news/pfizer-pfe-ceo-struggling-because-145115350.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "4fac2f94-3f6f-3573-b0e3-ed6389315d36",
      "content": {
        "id": "4fac2f94-3f6f-3573-b0e3-ed6389315d36",
        "contentType": "STORY",
        "title": "Pfizer (PFE) CEO’s Struggling Because Of “a Good Hand,” Says Jim Cramer",
        "description": "",
        "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them. On Tuesday, the stock dipped by 5.2% after the firm released its full-year 2026 guidance. The […]",
        "pubDate": "2025-12-19T14:51:15Z",
        "displayTime": "2025-12-19T14:51:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/ddb91ea345a3caa2bed91df10c8995bd",
          "originalWidth": 1920,
          "originalHeight": 1272,
          "caption": "Pfizer (PFE) CEO's Struggling Because Of \"a Good Hand,\" Says Jim Cramer",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FX7iP5u5zmCV2jrzGOzvvA--~B/aD0xMjcyO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/ddb91ea345a3caa2bed91df10c8995bd.cf.webp",
              "width": 1920,
              "height": 1272,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MYWwqgyghHg1GWNVfa79RA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ddb91ea345a3caa2bed91df10c8995bd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-ceo-struggling-because-145115350.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-ceo-struggling-because-145115350.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T14:50:22+00:00",
    "headline": "Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs",
    "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-couldn-t-stop-145022789.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ab2a1f66-2aed-3a18-891f-47fc1234232a",
      "content": {
        "id": "ab2a1f66-2aed-3a18-891f-47fc1234232a",
        "contentType": "STORY",
        "title": "Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs",
        "description": "",
        "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]",
        "pubDate": "2025-12-19T14:50:22Z",
        "displayTime": "2025-12-19T14:50:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53",
          "originalWidth": 1000,
          "originalHeight": 668,
          "caption": "Jim Cramer Couldn't Stop Gushing About Johnson & Johnson (JNJ)'s Cancer Drugs",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.1i2Xg8sqkYBwxzkIAC02w--~B/aD02Njg7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53.cf.webp",
              "width": 1000,
              "height": 668,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MUHt2SWlA2SDsXLMEXhTeg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-couldn-t-stop-145022789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-couldn-t-stop-145022789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T09:30:00+00:00",
    "headline": "Down 80%, Should You Buy the Dip on Moderna?",
    "summary": "Your decision on whether to invest now depends to some extent on your investment strategy.",
    "url": "https://www.fool.com/investing/2025/12/19/down-80-should-you-buy-the-dip-on-moderna/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "e406e15c-f46a-3c6f-891f-153addcaf7e4",
      "content": {
        "id": "e406e15c-f46a-3c6f-891f-153addcaf7e4",
        "contentType": "STORY",
        "title": "Down 80%, Should You Buy the Dip on Moderna?",
        "description": "",
        "summary": "Your decision on whether to invest now depends to some extent on your investment strategy.",
        "pubDate": "2025-12-19T09:30:00Z",
        "displayTime": "2025-12-19T09:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/1cadddbdf61f5428bcd51ff178dd39e9",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "An investor looks pensively at a laptop screen at home.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/durqZJ1rlVd.d6npOlKK2w--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/1cadddbdf61f5428bcd51ff178dd39e9.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dTcmh8yHlpiAfzh.UYZmKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/1cadddbdf61f5428bcd51ff178dd39e9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/19/down-80-should-you-buy-the-dip-on-moderna/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/down-80-buy-dip-moderna-093000960.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T04:33:54+00:00",
    "headline": "1 S&P 500 Stock with Impressive Fundamentals and 2 That Underwhelm",
    "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
    "url": "https://finance.yahoo.com/news/1-p-500-stock-impressive-043354556.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "bab04e04-b1e7-3e99-b8c5-63f8e66b52cd",
      "content": {
        "id": "bab04e04-b1e7-3e99-b8c5-63f8e66b52cd",
        "contentType": "STORY",
        "title": "1 S&P 500 Stock with Impressive Fundamentals and 2 That Underwhelm",
        "description": "",
        "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
        "pubDate": "2025-12-19T04:33:54Z",
        "displayTime": "2025-12-19T04:33:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/c33d5012ea1701a7be34c00d3064b11a",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "AVGO Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/n3Ln7U_MFdIYf7_witPBbA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/c33d5012ea1701a7be34c00d3064b11a.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mtUV7bXykTIqoQWBHdxzAA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/c33d5012ea1701a7be34c00d3064b11a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-p-500-stock-impressive-043354556.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-p-500-stock-impressive-043354556.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "AVGO"
            },
            {
              "symbol": "ALL"
            },
            {
              "symbol": "ALL-PH"
            },
            {
              "symbol": "ALL-PI"
            },
            {
              "symbol": "ALL-PJ"
            },
            {
              "symbol": "VTRS"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T01:50:00+00:00",
    "headline": "3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now",
    "summary": "The stocks listed here trade at forward earnings multiples of less than 18.",
    "url": "https://www.fool.com/investing/2025/12/18/3-absurdly-cheap-stocks-you-can-buy-for-less-than/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "1cc4b0c9-2111-346c-8ca7-23c082c2a920",
      "content": {
        "id": "1cc4b0c9-2111-346c-8ca7-23c082c2a920",
        "contentType": "STORY",
        "title": "3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now",
        "description": "",
        "summary": "The stocks listed here trade at forward earnings multiples of less than 18.",
        "pubDate": "2025-12-19T01:50:00Z",
        "displayTime": "2025-12-19T01:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/3b7f4cc4db694a851507571137a9bcc1",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A person in business clothing checks a smartphone.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EwNRHFGWIxTwbDxdeybkGQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/3b7f4cc4db694a851507571137a9bcc1.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hB8Q_CP0ba4ZTw9muy5qwg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3b7f4cc4db694a851507571137a9bcc1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/18/3-absurdly-cheap-stocks-you-can-buy-for-less-than/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-absurdly-cheap-stocks-buy-015000947.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "CVS"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T11:01:21+00:00",
    "headline": "Novo files for CagriSema approval; Merck and Pfizer’s trial win",
    "summary": "Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer trial",
    "url": "https://www.biopharmadive.com/news/novo-cagrisema-merck-pfizer-keytruda-padcev-gsk/808142/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "381d876d-019f-355f-95ed-426d2c5d943c",
      "content": {
        "id": "381d876d-019f-355f-95ed-426d2c5d943c",
        "contentType": "STORY",
        "title": "Novo files for CagriSema approval; Merck and Pfizer’s trial win",
        "description": "",
        "summary": "Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer trial",
        "pubDate": "2025-12-19T11:01:21Z",
        "displayTime": "2025-12-19T11:01:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/novo-cagrisema-merck-pfizer-keytruda-padcev-gsk/808142/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-files-cagrisema-approval-merck-110121453.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "CAMP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T19:44:47+00:00",
    "headline": "Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump",
    "summary": "Dow Jones stock Merck struck a Most Favored Nation agreement with the Trump administration on Friday, joining other pharma bellwethers.",
    "url": "https://www.investors.com/news/technology/merck-most-favored-nation-drug-pricing-deal/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "2cb395b6-a638-3e88-a9aa-fb560f3deaa3",
      "content": {
        "id": "2cb395b6-a638-3e88-a9aa-fb560f3deaa3",
        "contentType": "STORY",
        "title": "Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump",
        "description": "",
        "summary": "Dow Jones stock Merck struck a Most Favored Nation agreement with the Trump administration on Friday, joining other pharma bellwethers.",
        "pubDate": "2025-12-19T19:44:47Z",
        "displayTime": "2025-12-19T19:44:47Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/2cb395b6-a638-3e88-a9aa-fb560f3deaa3/dow-jones-merck-other.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/3a897c85d50513809da70438e2285a69",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J52TnzuAhPRkxQcQYwjwUg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/3a897c85d50513809da70438e2285a69.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Jcx0qKVoS.mXc1N2ud7p5Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/3a897c85d50513809da70438e2285a69.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/merck-most-favored-nation-drug-pricing-deal/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T17:15:00+00:00",
    "headline": "Pharma's $370B Bet on America: The ETF Plays for 2026",
    "summary": "Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.",
    "url": "https://finance.yahoo.com/news/pharmas-370b-bet-america-etf-171500181.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "33fcaabd-c7f4-3fb2-94b5-2bcf58713c2e",
      "content": {
        "id": "33fcaabd-c7f4-3fb2-94b5-2bcf58713c2e",
        "contentType": "STORY",
        "title": "Pharma's $370B Bet on America: The ETF Plays for 2026",
        "description": "",
        "summary": "Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.",
        "pubDate": "2025-12-19T17:15:00Z",
        "displayTime": "2025-12-19T17:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/829e973ee4e0f9b8c53ec82f52e62f8e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZemfjVvYBRw3W8.nEBguuA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/829e973ee4e0f9b8c53ec82f52e62f8e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wNN8n2_YU3n6CER2COkU_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/829e973ee4e0f9b8c53ec82f52e62f8e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pharmas-370b-bet-america-etf-171500181.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pharmas-370b-bet-america-etf-171500181.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "IHE"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "NVSEF"
            },
            {
              "symbol": "ABT"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PJP"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "PPH"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T16:42:00+00:00",
    "headline": "White House Will Announce Pricing Deals With More Drugmakers Friday",
    "summary": "The Trump administration has talked tough about cutting drug prices, but the impacts of the deals with drug companies announced thus far have been limited.",
    "url": "https://www.barrons.com/articles/trump-drug-prices-pharmaceutical-9a04e4f5?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "af431dd1-182d-36f0-bd26-58acf64a3210",
      "content": {
        "id": "af431dd1-182d-36f0-bd26-58acf64a3210",
        "contentType": "STORY",
        "title": "White House Will Announce Pricing Deals With More Drugmakers Friday",
        "description": "",
        "summary": "The Trump administration has talked tough about cutting drug prices, but the impacts of the deals with drug companies announced thus far have been limited.",
        "pubDate": "2025-12-19T16:42:00Z",
        "displayTime": "2025-12-19T16:42:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/af431dd1-182d-36f0-bd26-58acf64a3210/white-house-will-announce.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/b84973a4d2302435aaade39667770556",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0M1QXHPJoerma0suNcmL3w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/b84973a4d2302435aaade39667770556.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/S12Xvmf6XJVD1f.9zynb9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/b84973a4d2302435aaade39667770556.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/trump-drug-prices-pharmaceutical-9a04e4f5?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T15:46:00+00:00",
    "headline": "Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock",
    "summary": "Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.",
    "url": "https://finance.yahoo.com/news/pfizer-down-issues-muted-2026-154600786.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "9418b507-4909-32a3-933b-cd93a6c3ec0a",
      "content": {
        "id": "9418b507-4909-32a3-933b-cd93a6c3ec0a",
        "contentType": "STORY",
        "title": "Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock",
        "description": "",
        "summary": "Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.",
        "pubDate": "2025-12-19T15:46:00Z",
        "displayTime": "2025-12-19T15:46:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YqcOBKMNrThKvJSga1KIbw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_Vj9Bix098SQE5mY9G0P2w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-down-issues-muted-2026-154600786.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-down-issues-muted-2026-154600786.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T21:26:00+00:00",
    "headline": "New York State's 2025 Emerging Technology Advisory Board Releases Final Report to Boost Biotech Innovation, Commercialization and Public Health Impact",
    "summary": "Today, the New York State Emerging Technology Advisory Board (ETAB) released its final report of recommendations to Governor Kathy Hochul. Led by co-chairs Deborah W. Brooks, CEO and co-founder of The Michael J. Fox Foundation for Parkinson's Research (MJFF), and Andrew Baum, chief strategy and innovation officer of Pfizer, the ETAB's recommendations aim to bolster New York's position as a global biotechnology hub and as a place where innovation fuels healthier, stronger communities.",
    "url": "https://finance.yahoo.com/news/york-states-2025-emerging-technology-212600267.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "58e6be4b-e219-3be9-8e3d-9911ec21f672",
      "content": {
        "id": "58e6be4b-e219-3be9-8e3d-9911ec21f672",
        "contentType": "STORY",
        "title": "New York State's 2025 Emerging Technology Advisory Board Releases Final Report to Boost Biotech Innovation, Commercialization and Public Health Impact",
        "description": "",
        "summary": "Today, the New York State Emerging Technology Advisory Board (ETAB) released its final report of recommendations to Governor Kathy Hochul. Led by co-chairs Deborah W. Brooks, CEO and co-founder of The Michael J. Fox Foundation for Parkinson's Research (MJFF), and Andrew Baum, chief strategy and innovation officer of Pfizer, the ETAB's recommendations aim to bolster New York's position as a global biotechnology hub and as a place where innovation fuels healthier, stronger communities.",
        "pubDate": "2025-12-19T21:26:00Z",
        "displayTime": "2025-12-19T21:26:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/50a27bd58b0f61dbddd0f0ca9880e678",
          "originalWidth": 400,
          "originalHeight": 270,
          "caption": "From left to right: Andrew Baum, Chief Strategy and Innovation Officer, Pfizer; Deborah W. Brooks, CEO and Co-Founder, The Michael J. Fox Foundation; New York Governor Kathy Hochul; Anthony Shorris, Partner, McKinsey & Company",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZcST5n1LKdTGmN3VmtNymw--~B/aD0yNzA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/50a27bd58b0f61dbddd0f0ca9880e678.cf.webp",
              "width": 400,
              "height": 270,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EOOwrS2BGhZPo_2aDB6FZA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/50a27bd58b0f61dbddd0f0ca9880e678.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/york-states-2025-emerging-technology-212600267.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/york-states-2025-emerging-technology-212600267.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T21:09:45+00:00",
    "headline": "Nine Drugmakers Strike Deals With Trump, With More to Come",
    "summary": "The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad.  “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.",
    "url": "https://finance.yahoo.com/news/nine-drugmakers-strike-deals-trump-193259194.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "4b465f35-8d3c-3995-a661-e4cd7f05b432",
      "content": {
        "id": "4b465f35-8d3c-3995-a661-e4cd7f05b432",
        "contentType": "STORY",
        "title": "Nine Drugmakers Strike Deals With Trump, With More to Come",
        "description": "",
        "summary": "The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad.  “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.",
        "pubDate": "2025-12-19T21:09:45Z",
        "displayTime": "2025-12-19T21:09:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/0ea477c2d30cc141387bcde902150c0a",
          "originalWidth": 2000,
          "originalHeight": 1333,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yPpId7n3nm6_XRF64S8wVg--~B/aD0xMzMzO3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/0ea477c2d30cc141387bcde902150c0a.cf.webp",
              "width": 2000,
              "height": 1333,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PHjfupuwaI2I5LGARA8SaA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/0ea477c2d30cc141387bcde902150c0a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nine-drugmakers-strike-deals-trump-193259194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nine-drugmakers-strike-deals-trump-193259194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T21:07:00+00:00",
    "headline": "Lilly Shares Have Tripled on Weight-Loss Drugs. Why the Stock Looks Cheap.",
    "summary": "The growth potential of the weight-loss market could explode with advances, notably GLP-1 pills, and broader insurance coverage. That should change both health outcomes and the way Americas buy and consume food.",
    "url": "https://www.barrons.com/articles/eli-lilly-stock-price-weight-loss-drugs-ec064ec5?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "cbe982ce-03ff-36aa-830d-8dab863a2362",
      "content": {
        "id": "cbe982ce-03ff-36aa-830d-8dab863a2362",
        "contentType": "STORY",
        "title": "Lilly Shares Have Tripled on Weight-Loss Drugs. Why the Stock Looks Cheap.",
        "description": "",
        "summary": "The growth potential of the weight-loss market could explode with advances, notably GLP-1 pills, and broader insurance coverage. That should change both health outcomes and the way Americas buy and consume food.",
        "pubDate": "2025-12-19T21:07:00Z",
        "displayTime": "2025-12-19T21:07:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cbe982ce-03ff-36aa-830d-8dab863a2362/lilly-shares-have-tripled-on.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/44f7aff5d119d99ce24fdbd15b263a6a",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aRnbDLpqfc5mD3lZI61TQA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/44f7aff5d119d99ce24fdbd15b263a6a.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MpEOz9Fx98Tg1WHNumWgzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/44f7aff5d119d99ce24fdbd15b263a6a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/eli-lilly-stock-price-weight-loss-drugs-ec064ec5?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T20:20:00+00:00",
    "headline": "Better Buy in 2026: Pfizer or Merck?",
    "summary": "This year has been one to forget for these pharmaceutical giants.",
    "url": "https://www.fool.com/investing/2025/12/19/better-buy-in-2026-pfizer-or-merck/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "978cc8b4-eda2-3a44-8084-5105e28e1bc9",
      "content": {
        "id": "978cc8b4-eda2-3a44-8084-5105e28e1bc9",
        "contentType": "STORY",
        "title": "Better Buy in 2026: Pfizer or Merck?",
        "description": "",
        "summary": "This year has been one to forget for these pharmaceutical giants.",
        "pubDate": "2025-12-19T20:20:00Z",
        "displayTime": "2025-12-19T20:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/4cc173b17304113970d31d379090c2b8",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Doctor talking to patient.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/awC9dwGn1n510BXC1DLdVg--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/4cc173b17304113970d31d379090c2b8.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Fvj30fbjn7rtka8FSKyCtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/4cc173b17304113970d31d379090c2b8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/19/better-buy-in-2026-pfizer-or-merck/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/better-buy-2026-pfizer-merck-202000176.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T20:14:00+00:00",
    "headline": "White House Cuts Drug-Pricing Deals With Pharma Companies, Tilting System Toward Self-Pay",
    "summary": "The Trump administration has talked tough on drug prices, but the impact of its deals with drugmakers so far has been limited.",
    "url": "https://www.barrons.com/articles/trump-drug-prices-pharmaceutical-9a04e4f5?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "af431dd1-182d-36f0-bd26-58acf64a3210",
      "content": {
        "id": "af431dd1-182d-36f0-bd26-58acf64a3210",
        "contentType": "STORY",
        "title": "White House Cuts Drug-Pricing Deals With Pharma Companies, Tilting System Toward Self-Pay",
        "description": "",
        "summary": "The Trump administration has talked tough on drug prices, but the impact of its deals with drugmakers so far has been limited.",
        "pubDate": "2025-12-19T20:14:00Z",
        "displayTime": "2025-12-19T20:14:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/af431dd1-182d-36f0-bd26-58acf64a3210/white-house-cuts-drug-pricing.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/b84973a4d2302435aaade39667770556",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0M1QXHPJoerma0suNcmL3w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/b84973a4d2302435aaade39667770556.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/S12Xvmf6XJVD1f.9zynb9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/b84973a4d2302435aaade39667770556.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/trump-drug-prices-pharmaceutical-9a04e4f5?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]